Central Nervous System
Ionis and AstraZeneca report additional positive topline data from a Phase III ATTRv-PN trial
Ionis Pharmaceuticals and AstraZeneca announced further positive topline data from a Phase III NEURO-TTRansform trial investigating eplontersen in patients with…
FDA AdCom overwhelmingly supports accelerated approval for Biogen’s tofersen in ALS
On March 22, an FDA Advisory Committee (AdCom) unanimously voted in favor of accelerated approval for Biogen’s tofersen for a…
RayzeBio concludes subject enrolment in neuroendocrine tumours trial
RayzeBio has completed participant enrolment in the Phase Ib portion of the Phase Ib/III ACTION-1 trial of RYZ101 (Actinium-225 DOTATATE)…
Pipeline Moves: advancement prospects jump for Parkinson’s disease stem cell therapy
This week on Pipeline Moves, we start by looking at completions of Phase II trials in Parkinson’s disease and asthma,…
Duchenne muscular dystrophy: major trials and events to watch in 2023
In 2023, two potential FDA approvals and three late-stage clinical trial readouts could shift the treatment landscape for Duchenne muscular…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
University of Birmingham reports new Phase II trial of exenatide for IIH
A new Phase II trial led by the University of Birmingham and University Hospitals Birmingham neurologists has found that an…
BioVie achieves revised enrolment target in trial of NE3107 for Alzheimer’s
BioVie has achieved its revised enrolment target of 400 subjects in the NM101 Phase III trial of NE3107 for the…
Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease
Acumen Pharmaceuticals plans to conduct a Phase II or Phase II/III clinical trial investigating the monoclonal antibody ACU193 in patients…
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The…
Pipeline Moves: positive topline results for epilepsy drug, advancement prospects jump
This week on Pipeline Moves, we start off on a good note by looking at positive topline results from a…